Kevin Harrington, an original “Shark” from the Emmy Award-winning TV show Shark Tank and the brains behind the “As Seen on TV” brand, has announced his latest venture— an early investment in the emerging alcohol detox drink, Unbuzzd. Harrington, who has launched over 1,000 products across more than 100 countries, generating over $6 billion in global sales, sees Unbuzzd as a potential game-changer in the functional beverage market.
Full article in Forbes.
“It’s a revolution in how we recover from alcohol,” Harrington claims.
RELATED: Adding Quantum to Reverse Split Watch List.
Harrington describes Unbuzzd as more than just a hangover remedy, describing the detox drink as a “disruptive innovation built on science,” aimed at transforming how people think about alcohol recovery. Unlike traditional hangover cures that simply alleviate symptoms, Unbuzzd takes a proactive approach by helping the body process alcohol more efficiently. The goal is to restore mental clarity, boost cognitive function, and allow consumers to enjoy alcohol responsibly while still waking up feeling refreshed the next day.
The research and development team at Quantum Biopharma, the biopharmaceutical company behind Unbuzzd, emphasizes that the unique formula of natural ingredients is what sets the product apart from the competition. Quantum Biopharma (QNTM) is already known for its work in neurodegenerative and metabolic disorders, and they’ve applied their expertise to create a drink that goes beyond simple hydration.
A Closer Look at the Ingredients
Unbuzzd’s natural ingredients each play a vital role in promoting recovery after alcohol consumption. Green tea, for example, is rich in antioxidants that help reduce oxidative stress and support detoxification, while its hydrating properties— combined with the metabolism-boosting effects of caffeine and L-theanine— help alleviate hangover symptoms and enhance mental clarity.
Milk thistle, another key ingredient, contains silymarin, a compound that supports liver function by aiding in the repair of liver cellular damaged by alcohol. This detoxifying agent is well known in natural medicine for promoting liver health.
Phenylalanine, an essential amino acid found in Unbuzzd, helps produce neurotransmitters like dopamine, which can restore mental balance and improve mood after binge drinking. It also plays a role in reducing alcohol-related fatigue by helping replenish neurotransmitter levels that may be depleted from excessive alcohol intake.
The formula also contains Dihydromyricetin (DHM), extracted from the fruit of the Japanese raisin tree, which accelerates the body’s alcohol metabolism while offering the added benefit of protecting the liver. Meanwhile, Methylliberine, a compound isolated from sources like coffee beans, tea, cola nuts, guarana, cocoa, and yerba mate, is known for boosting energy, enhancing concentration, improving motivation, and elevating mood.
A New Era in Functional Beverages
The makers of unbuzzd believe that 2024 will mark the beginning of a new era for functional beverages aimed at supporting overall wellness after social occasions. With the U.S. functional beverage market booming, the product is entering a competitive but promising space.
According to NielsenIQ, the U.S. functional beverage market saw over 53,000 unique UPC codes last year, spanning a wide range of drinks like energy drinks, sports beverages, shakes, teas, and more. These drinks are promoted for their health-boosting benefits, ranging from mental clarity to physical performance.
Unbuzzd, with its focus on alcohol recovery, is poised to tap into this growing trend. The rising popularity of detox products among fitness enthusiasts and health-conscious consumers is expected to drive significant market growth in the coming years. Taste wise reports that interest in hydrating foods and beverages grew by 12.8% last year alone.
“Why are alcohol drinkers reaching for recovery drinks? Because life goes on after cocktails,” says John Duffy, CEO of Celly Nutrition and former executive at Coca-Cola. Duffy believes Unbuzzd meets a critical consumer need by helping people enjoy their social lives without suffering the next day.
Strategic Growth and Market Expansion
As of 2023, the global detox drinks market was valued at USD 5.36 billion, and it’s projected to grow to USD 9.66 billion by 2032, with a compound annual growth rate (CAGR) of 6.95%. In the U.S. alone, the detox market is expected to reach USD 2.08 billion by 2032, largely driven by the demand for healthier, non-carbonated beverages.
Quantum Biopharma strategically spun off Unbuzzd to Celly Nutrition, retaining a 25.71% stake in the company. Celly Nutrition has since secured a master distribution agreement with FUSION Consulting Group, a leading distributor of health-conscious food and beverages across Puerto Rico, the Caribbean, and parts of Central and South America.
This partnership is expected to bring unbuzzd to key vacation destinations, where alcohol consumption is often part of the experience. Through FUSION’s distribution network, Unbuzzd will reach major retailers like Walmart, Walgreens, CVS, Costco, and others.
“Having been a part of many game-changing products, including Celsius, I believe unbuzzd is the next big innovation in the consumer products space,” says Gerry David, Co-Chair of Celly Nutrition’s Board and former CEO of Celsius Holdings, Inc.
Harrington, who was instrumental in the creation of Celsius’ influencer marketing program and has been involved in some of the world’s most successful consumer products, agrees. With unbuzzd, he sees a groundbreaking product that could revolutionize the way people recover from alcohol, helping them enjoy life while staying in control.
Interview with Jason Sawyer Quantum VP Finance
$700 Million Contingency Law Suit Against Canadian Broker Dealers CIBC World Markets and RBC Dominion Securities
“In the 21 years our team has been prosecuting market manipulation cases against Wall Street, I believe this could be one of the top 5 biggest spoofing/market manipulation cases we have handled.” Christian Attar and Freedman Normand Friedland LLP
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Forward-Looking Information
This press release contains certain “forward-looking statements” within the meaning of applicable Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as “believes”, “anticipates”, “expects”, “is expected”, “scheduled”, “estimates”, “pending”, “intends”, “plans”, “forecasts”, “targets”, or “hopes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “will”, “should” “might”, “will be taken”, or “occur” and similar expressions) are not statements of historical fact and may be forward-looking statements. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s focus on the research and development of Lucid-MS to prevent and reverse myelin degradation; the Company’s Lucid-21-302 clinical development program in multiple sclerosis advancing towards human phase-2 efficacy trials; the Company’s intention to utilize its large tax loss to offset future tax payable obligations against future profits; the Company’s intention to retain 100% of the rights to develop products for pharmaceutical and medical uses; the Company’s intention to maintain a portfolio of strategic investments through FSD Strategic Investments Inc.; the Company’s belief that its share price does not affect its current financial position and recent operational improvements and that a strong cash and cash equivalents provide a solid foundation for operations and potential growth opportunities.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s assessment of market conditions, its ability to gain market share, and its potential competitive edge are accurate; the Company will have the ability to carry out its plans with respect to its new innovation and offerings, including its ability to conduct research and development of Lucid-MS; the Company’s Lucid-21-302 clinical development program in multiple sclerosis will advance towards human phase-2 efficacy trials; the Company will retain 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses; the Company will seek new business opportunities; the Company will increase efficiency in its processes and partnerships; the Company will have the ability to carry out its other goals and objectives; the Company is accurate in its belief that its share price does not current financial position and recent operational improvements; that a strong cash and cash equivalents will provide a solid foundation for operations and potential growth opportunities.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company being inaccurate in its belief that its share price does not current financial position and recent operational improvements; and that a strong cash and cash equivalents will not provide a solid foundation for operations and potential growth opportunities; the Company’s inability to carry out its plans with respect to its new innovation and offerings; the Company’s inability to utilize its tax loss; the Company’s inability to retain 100% of the rights to develop products for pharmaceutical or medical uses; the Company’s inability to enhance its product development capabilities and/or maintain a portfolio of strategic investments; the Company’s Lucid-21-302 clinical development program in multiple sclerosis not advancing towards human phase-2 efficacy trials; and the risks discussed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, final short form base shelf prospectus dated December 22, 2023 and registration statement on Form F-3 containing a base shelf prospectus, each under the heading “Risk Factors”. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Readers are cautioned that the foregoing list is not exhaustive. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events, or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: 1-833-571-1811
